The stock may react negatively to the full-year revenue decline and weak 2026 outlook for BetterHelp, despite improved profitability. Traders should monitor Integrated Care's ability to grow and whether cost discipline can offset top-line weakness. The significant cash burn ($517M) warrants attention despite positive operating cash flow.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $5.35entry
- T+1 · 9mo ago −1.68%α −1.20% · $5.26
- T+5 · 9mo ago −4.30%α −3.14% · $5.12
- T+20 · 8mo ago +3.18%α +9.59% · $5.52
- T+60 · 6mo ago +22.80%α +14.63% · $6.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teladoc Health reported flat Q4 revenue of $642.3 million (0% YoY) and full-year 2025 revenue down 2% YoY to $2.53 billion. Net loss narrowed significantly to $200.3 million from $1.0 billion in 2024, driven by a large goodwill impairment in the prior year. Adjusted EBITDA rose 12% in Q4 but fell 10% for the full year. The company issued 2026 guidance projecting revenue of $2.47B–$2.59B and adjusted EBITDA of $266M–$308M, with Integrated Care expected to grow slightly and BetterHelp expected to decline.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $642.3M (flat YoY); Full Year 2025 revenue: $2.53B (down 2% YoY)
- Q4 adjusted EBITDA: $83.8M (up 12% YoY); Full Year adjusted EBITDA: $281.1M (down 10% YoY)
- Full Year 2025 net loss: $200.3M (vs. $1.0B loss in 2024), including a $71.8M goodwill impairment
- Integrated Care segment revenue grew 3% for the year; BetterHelp revenue declined 9%
- 2026 guidance: Revenue $2.47B–$2.59B; Adjusted EBITDA $266M–$308M; BetterHelp revenue expected to decline 0.5% to 7%
- Cash and equivalents ended 2025 at $781.1M, down from $1.3B at end of 2024
Financial Impact
Revenue declined 2% for the full year, with EBITDA down 10%. 2026 guidance suggests continued softness, particularly in the BetterHelp segment which is expected to contract further.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Integrated Care | $1.6B | +3.0% |
| BetterHelp | $950.4M | -9.0% |
Risk Factors
- BetterHelp segment continues to deteriorate, with revenue down 9% and guidance for further decline
- Significant cash burn: cash balance dropped from $1.3B to $781M in one year, partly due to $551M repayment of convertible notes
- Reliance on cost-cutting and margin improvement rather than top-line growth to drive profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001477449-26-000010 |
| Document: tdoc-20260225.htm | 0001477449-26-000010 |
| Document: 0001477449-26-000010-index-headers.html | 0001477449-26-000010 |
| Document: 0001477449-26-000010-index.html | 0001477449-26-000010 |
| Document: 0001477449-26-000010.txt | 0001477449-26-000010 |
Track record
24 reports on TDOC
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +2.52% at T+1 after the Oct 28, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.60 Now $8.70 +1.22% settles Nov 17
- Nov 6, 202610d ago 144 Neutral 3/10 Entry $8.77 to $8.98 Now $8.70 −0.80% ▲ +2.39% +0.03% vs SPY
- Nov 3, 202613d ago 3 / PRESS-RELEASE Neutral 2/10 Entry $9.70 to $9.41 Now $8.70 −10.31% ▼ −2.99% +1.42% vs SPY
- Nov 3, 202614d ago PTAB Trial Neutral 3/10 Entry $8.89 to $9.70 Now $8.70 −2.14% ▲ +9.11% +7.46% vs SPY
- Oct 28, 202619d ago Press Release Bearish 6/10 No price data
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $8.73 to $8.51 Now $8.70 +0.34% ▲ +2.52% +0.75% vs SPY
- Oct 28, 202620d ago PTAB Trial Neutral 3/10 Entry $8.73 to $8.51 Now $8.70 −0.34% ▼ −2.52% −0.75% vs SPY
- Oct 8, 20265w ago SC 13G Neutral 3/10 Entry $5.54 to $5.77 Now $8.70 +57.04% ▲ +4.15% +3.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.09 to $5.89 Now $8.70 +42.86% ▼ −3.28% −2.54% vs SPY
- Sep 11, 20269w ago 144 Neutral 2/10 Entry $6.16 to $6.50 Now $8.70 +41.23% ▲ +5.52% +5.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers